Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07016724

Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Esophageal Squamous Cell Carcinoma Carcinoma Carcinoma, Squamous Cell Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Neoplasms, Squamous Cell

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

the First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

Location status: Recruiting

Location contact

Xiangbo Wan, Ph.D

CONTACT

[email protected]

0086-037166271152

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with esophageal squamous cell cancer;
  • staged with cT1N+M0/cT2-3N0-3M0;
  • experienced no cancer-related treatment;
  • ECOG 0-1;
  • Expected survival more than 6 months;
  • aimed at neoadjuvant therapy for surger;
  • have adquate organ function.

Exclusion criteria

  • diagnosed with other types of cancer during last five years;
  • have a tendency to bleed;
  • accepted any type of cancer-related therapy.

Treatment and study plan

cadonilizumab combined with neoadjuvant radiochemotherapy

Combination Product

Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.

Other names: neoadjuvant radiochemotherapy

neoadjuvant radiochemotherapy

Combination Product

Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.

Primary outcomes

  1. pCR

    Time frame: perioperative

    pathological complete response

Study contacts

Contact information is provided by the study sponsor or research team.

Fuwei Wang

CONTACT

[email protected]

0086-037166278517

Xiangbo Wan

CONTACT

[email protected]

0086-037166271152

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Zhengzhou University

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jun 12, 2025
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.